PVT1
Pvt1 oncogene (non-protein coding), also known as PVT1, is a long non-coding RNA gene.[1] In mice, this gene was identified as a breakpoint site in chromosome 6;15 translocations. These translocations are associated with murine plasmacytomas.[2] The equivalent translocation in humans is t(2;8), which is associated with a rare variant of Burkitt’s lymphoma.[3] In rats, this breakpoint was shown to be a common site of proviral integration in retrovirally induced T lymphomas.[4] Transcription of PVT1 is regulated by Myc.[5]
References
References
- ↑ “Entrez Gene: PVT1 Pvt1 oncogene homolog, MYC activator (mouse)”.
- ↑ Cory S, Graham M, Webb E, Corcoran L, Adams JM (1985). “Variant (6;15) translocations in murine plasmacytomas involve a chromosome 15 locus at least 72 kb from the c-myc oncogene”. EMBO J. 4 (3): 675–81. PMC 554241. PMID 3924592.
- ↑ Graham M, Adams JM (1986). “Chromosome 8 breakpoint far 3′ of the c-myc oncogene in a Burkitt’s lymphoma 2;8 variant translocation is equivalent to the murine pvt-1 locus”. EMBO J. 5 (11): 2845–51. PMC 1167233. PMID 3024964.
- ↑ Villeneuve L, Rassart E, Jolicoeur P, Graham M, Adams JM (1986). “Proviral integration site Mis-1 in rat thymomas corresponds to the pvt-1 translocation breakpoint in murine plasmacytomas”. Mol Cell Biol. 6 (5): 1834–7. PMC 367714. PMID 3785181.
- ↑ Carramusa L, Contino F, Ferro A, Minafra L, Perconti G, Giallongo A, et al. (2007). “The PVT-1 oncogene is a Myc protein target that is overexpressed in transformed cells”. J Cell Physiol. 213 (2): 511–8. doi:10.1002/jcp.21133. PMID 17503467.
Further reading
Further reading
- Guan Y, Kuo WL, Stilwell JL, et al. (2007). “Amplification of PVT1 contributes to the pathophysiology of ovarian and breast cancer”. Clin. Cancer Res. 13 (19): 5745–55. doi:10.1158/1078-0432.CCR-06-2882. PMID 17908964.
- Millis MP, Bowen D, Kingsley C, et al. (2007). “Variants in the plasmacytoma variant translocation gene (PVT1) are associated with end-stage renal disease attributed to type 1 diabetes”. Diabetes. 56 (12): 3027–32. doi:10.2337/db07-0675. PMID 17881614.
- Carramusa L, Contino F, Ferro A, et al. (2008). “The PVT-1 oncogene is a Myc protein target that is overexpressed in transformed cells”. J. Cell. Physiol. 213 (2): 511–8. doi:10.1002/jcp.21133. PMID 17503467.
- Hanson RL, Craig DW, Millis MP, et al. (2007). “Identification of PVT1 as a candidate gene for end-stage renal disease in type 2 diabetes using a pooling-based genome-wide single nucleotide polymorphism association study”. Diabetes. 56 (4): 975–83. doi:10.2337/db06-1072. PMID 17395743.
- Oh JH, Yang JO, Hahn Y, et al. (2006). “Transcriptome analysis of human gastric cancer”. Mamm. Genome. 16 (12): 942–54. doi:10.1007/s00335-005-0075-2. PMID 16341674.
- Ota T, Suzuki Y, Nishikawa T, et al. (2004). “Complete sequencing and characterization of 21,243 full-length human cDNAs”. Nat. Genet. 36 (1): 40–5. doi:10.1038/ng1285. PMID 14702039.
- Strausberg RL, Feingold EA, Grouse LH, et al. (2003). “Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences”. Proc. Natl. Acad. Sci. U.S.A. 99 (26): 16899–903. doi:10.1073/pnas.242603899. PMC 139241. PMID 12477932.
- Graham M, Adams JM (1987). “Chromosome 8 breakpoint far 3′ of the c-myc oncogene in a Burkitt’s lymphoma 2;8 variant translocation is equivalent to the murine pvt-1 locus”. EMBO J. 5 (11): 2845–51. PMC 1167233. PMID 3024964.
- Shtivelman E, Bishop JM (1989). “The PVT gene frequently amplifies with MYC in tumor cells”. Mol. Cell. Biol. 9 (3): 1148–54. PMC 362705. PMID 2725491.
- Shtivelman E, Henglein B, Groitl P, et al. (1989). “Identification of a human transcription unit affected by the variant chromosomal translocations 2;8 and 8;22 of Burkitt lymphoma”. Proc. Natl. Acad. Sci. U.S.A. 86 (9): 3257–60. doi:10.1073/pnas.86.9.3257. PMC 287109. PMID 2470097.
- Shtivelman E, Bishop JM (1990). “Effects of translocations on transcription from PVT”. Mol. Cell. Biol. 10 (4): 1835–9. PMC 362296. PMID 2181290.
Looking for the patient version?
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH